ExpreS2ion Biotech (EXPRS2) BioStock Life Science Presentation summary

Company overview and platform

• Listed on Nasdaq First North Growth Market since 2016, with 100% ownership of ExpreS2ion Biotechnologies ApS and 34% of AdaptVac ApS.

• ExpreS2ion's proprietary protein production platform supports a vaccine pipeline and CRO business.

• AdaptVac's VLP platform is used in the breast cancer vaccine candidate ES2B-C001.

Breast cancer market and unmet need

• HER2 is overexpressed in about 25% of breast cancer tumors, linked to more aggressive disease and higher mortality.

• Over 180,000 annual diagnoses of HER2+ breast cancer in major markets, with significant subpopulations for HER2low and HER2neg.

• Breast cancer leads to approximately 685,000 deaths globally each year.

ES2B-C001 vaccine design and advantages

• Combines full-length HER2 antigen with highly immunogenic VLP technology for a strong polyclonal antibody response.

• Presents a wide range of epitopes, potentially effective in tumors resistant to monoclonal antibodies.

• Off-the-shelf, scalable, and cost-effective, with a validated safety profile.